SynthesisBMC gastroenterology2026
Effectiveness and safety of vedolizumab in real-world studies in Asian patients with inflammatory bowel disease: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the real-world effectiveness and safety of vedolizumab (VDZ) in Asian patients with IBD, including Crohn's disease (CD) and Ulcerative colitis (UC).
methodsWe systematically searched PubMed, EMBASE, the Cochrane Library, Web of Science, CBM, CNKI, Wanfang, and VIP for real-world studies assessing intravenous VDZ in Asian IBD patients. Primary outcomes were clinical remission, response and endoscopic remission. Secondary outcomes encompassed corticosteroid-free clinical remission, endoscopic response, complete endoscopic remission, C-reactive protein remission, faecal calprotectin normalization, treatment persistence rate and safety variables. Meta-analysis was performed for CD and UC across induction (6-14 weeks), medium term (22-30 weeks), and long term (over 48 weeks) using a random-effects model.
resultsTwenty-nine studies with 2395 patients were included. Induction clinical remission and response was 61.15% and 57.48% for CD, and 40.07% and 64.72% for UC. Medium-term clinical remission and response was 60.72% and 64.32% for CD, and 43.51% and 64.87% for UC. Long-term clinical remission and response for CD was 45.83% and 44.55%, for UC was 56.14% and 61.35%. Endoscopic remission improved across induction, medium term, and long-term for CD (11.11%, 18.41% and 36.42%) and UC (43.19%, 54.27% and 66.72%). Within the longest follow up of 52 weeks, adverse event rate ranged widely from 6.67% to 61.54% for CD and 29.69% to 75.38% for UC. Chinese patients and both biologic-naïve and biologic-experienced patients showed similar favorable outcomes.
conclusionVDZ demonstrated overall favourable effectiveness in Asian IBD patients, with a safety profile aligned with global data.
trial registrationThe protocol was registered on National Institution for Health and Care Research (registration number CRD420251000408).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.